key: cord-0952103-d7iziec6 authors: Giani, Elisa; Dovc, Klemen; Dos Santos, Tiago Jeronimo; Chobot, Agata; Braune, Katarina; Cardona‐Hernandez, Roque; De Beaufort, Carine; Scaramuzza, Andrea E. title: Telemedicine and COVID‐19 pandemic: The perfect storm to mark a change in diabetes care. Results from a world‐wide cross‐sectional web‐based survey date: 2021-11-16 journal: Pediatr Diabetes DOI: 10.1111/pedi.13272 sha: d60cecdd0f51d48b8d4801a868a514104f6a7847 doc_id: 952103 cord_uid: d7iziec6 BACKGROUND: Telemedicine for routine care of people with diabetes (PwD) during the COVID‐19 pandemic rapidly increased in many countries, helping to address the several barriers usually seen. OBJECTIVE: This study aimed to describe healthcare professionals' (HCPs) experience on telemedicine use in diabetes care and investigate the changes and challenges associated with its implementation. METHODS: A cross‐sectional electronic survey was distributed through the global network of JENIOUS members of ISPAD. Respondents' professional and practice profiles, clinic sizes, their country of practice, and data regarding local telemedicine practices during COVID‐19 pandemic were investigated. RESULTS: Answers from 209 HCPs from 33 countries were analyzed. During the pandemic, the proportion of PwD receiving telemedicine visits increased from <10% (65.1% of responders) to >50% (66.5%). There was an increase in specific privacy requirements for remote visits (37.3% to 75.6%), data protection policies (42.6% to 74.2%) and reimbursement for remote care (from 41.1% to 76.6%). Overall, 83.3% HCPs reported to be satisfied with the use of telemedicine. Some concerns (17.5%) about the complexity and heterogeneity of the digital platforms to be managed in everyday practice remain, feeding the need for unifying and making interoperable the tools for remote care. Also, 45.5% of professionals reported to feel stressed by the need for extra‐time for telemedicine consultations. CONCLUSIONS: Telemedicine was rapidly and broadly adopted during the pandemic globally. Some issues related to its use were promptly addressed by local institutions. Challenges with the use of different platforms and for the need of extra‐time still remain to be solved. The coronavirus disease 2019 (COVID-19) pandemic dramatically impacted health care systems worldwide, restraining the ability to maintain consistent consultations for people with chronic conditions. 1, 2 This tremendous crisis put additional burden on most healthcare systems but, at the same time, created new opportunities for change, marking a historical revolution in the ways of seeking and supplying medical care. 3 The adoption of telemedicine in a broad spectrum of medical specialties, including diabetes care, posed a major transition over the last 2 years. 4, 5 This was facilitated by a continuous uptake of new technological tools to collect, transfer, and analyze diabetes data. 4, [6] [7] [8] Nevertheless, the use of telemedicine remained limited in the past years due to several barriers, including the lack of guidance for data management and privacy, inadequate reimbursement policies, challenges to access diabetes technologies, need for patients and healthcare to become familiar with various digital tools. 9 During the first year of the pandemic, the adoption of telemedicine increased rapidly and became a common practice in many diabetes centers, 10 making it possible to limit further negative implications of the COVID-19 on youths with diabetes. 6, 7 The aim of the present study was to describe healthcare professionals' (HCPs) experiences about telemedicine use in diabetes centers worldwide. A cross-sectional electronic survey was conducted from October 2020 to April 2021 using Google Forms (Google LLC, Mountain View, CA). This allowed responses to be saved and subsequently downloaded in spreadsheet format. The full version of the survey and answers are available in Appendix S1. Questions were developed by four JENIOUS members. A direct web link and consent to participate in the survey was sent to International Society for Pediatric and Adolescent Diabetes (ISPAD) and JENIOUS members by email and social media platforms. The survey questions (34) were divided into four sections that captured information on responders' professional and practice profiles, sizes of their clinic, country of practice, and the impact of telemedicine regarding: (i) frequencies of use of different tools applied to telemedicine, (ii) perceived skills in the use of such technologies, The online survey was completed by 209 HCPs from 33 countries. Most of the participants were females (74.6%), median age 42 years (range 26-80 years). Most HCPs were pediatric endocrinologists/ diabetologists (67.5%), working in a healthcare setting providing care to more than 500 (32%) or between 200 and 499 (28%) people with diabetes (PwD). Before the pandemic, one third of the HCPs used telemedicine for less than 10% of pediatric PwD, and another third did not use telemedicine at all. During the local lockdowns, the use of telemedicine increasedabout 40% HCPs adopted remote visits to the standard care for more than 75% of PwD. The most frequently used tools included video call software Data privacy rules specific for remote contacts were absent in most countries before the pandemic (62.7% of responders) and introduced afterwards (75.6%). Similarly, specific telemedicine data protection policies were not present earlier in most cases (57.4%) became available during the pandemic (74.2%). Before COVID-19, telemedicine consultations were not reimbursed by the local health care systems or insurance companies in 58.9% of answers, while during the pandemic only 23.4% remained without reimbursement. Most HCPs rated their skills "adequate" or "expert" in downloading data from glucometers (93%), pumps (86%), and sensors (86%); in the analysis of glucometer data (97%), pump data (92%), and sensor data (95%); in using platforms for data analysis (84%). All participants agreed (36.4%) or strongly agreed (63.2%) that telemedicine may enhance in-person visits, and 43% agreed or strongly agreed that remote visits might even replace in-person contacts. Most HCPs evaluated the impact of telemedicine as non-inferior or superior to in-person visits on pediatric PwD's ability to reach gly- About half of HCPs (56%) did not perceive telemedicine to increase inappropriate referrals. Few (13%), experienced feelings of loneliness when using telemedicine because unable to share their concerns with colleagues. The satisfaction using telemedicine in clinical practice during the pandemic was high (very satisfied 29.2%, completely satisfied 6.7%) or moderate (moderately satisfied 47.4%). Suggestions from participants on how to improve their personal experience with telemedicine are summarized in Table 1 . One of the most requested changes for a further and easier use of telemedicine is to unify the available platforms and make them interoperable. T A B L E 1 HCPs' suggested strategies to improve the use of telemedicine This study reports HCPs experiences on the rapid shift in diabetes care towards telemedicine worldwide. The COVID-19 pandemic accelerated an already ongoing process of digital transformation in healthcare and posed new challenges and opportunities to patients, their families, and HCPs alike. 4 Practical solutions to overcome institutional barriers and technical issues related with remote consultations were made available in several countries. HCPs reported changes in local regulations for data protection and privacy for telemedicine, as well as the introduction of specific reimbursements. 11 Lee JM et al. documented the increase of telemedicine visits from <1% before the pandemic to 95.2% in April 2020 with most sites reporting reimbursement for video and telephone visits. 12 Similar data were published internationally. 7, 13 Appropriate devices and platforms to facilitate teleconsultations were also quickly made available in majority of the settings. Most In this survey, burden in the use of telemedicine was related with the difficulties to integrate the use of telehealth in everyday practice, the complexity and lack of interoperability of the platforms and the need of extra-time, as reported by Frielitz et al. 18 Recommendations from the virtual diabetes care expert panel identified the poor data integration among devices and the limited interoperability of platforms as major barriers concurring to clinicians' burnout. 9 Moreover, inadequate or inconsistent reimbursements and local disparities remain an obstacle to the wider adoption of telemedicine. 9, 11 The strength of this study is to represent HCPs' experience and challenges with telemedicine worldwide. HCPs suggestions on how to enhance telemedicine can help tailoring new healthcare models to support the implementation of telehealth also after the pandemic. A limitation is that respondents were primarily active members of an international medical society, from large care centers, therefore, the results may not be generalizable. However, our results align with other studies including different target populations. [11] [12] [13] 18, 19 We acknowledge a broad data collection time frame, which allowed to reduce the differences in the time of COVID-19 recrudescence/relapse in different countries. Despite this it may represent only the initial stage of a process still ongoing in some areas. In conclusion, this international survey reports the rapid changes made in most countries to overcome some of the barriers to telemedicine during the pandemic. Telemedicine has been experienced positively and adopted by most of the HCPs who participated in this survey and may constitute an alternative to the standard care. Several obstacles still need to be addressed for bringing telemedicine as a standard of care. The study was conducted on behalf of the ISPAD group of young investigators (JENIOUS group). The authors thank all the participants for their study participation. A list of the contributing collaborators is fully available in the Supplemental Materials. Additional supporting information may be found in the online version of the article at the publisher's website. How to cite this article: Giani E, Dovc K, Dos Santos TJ, et al. Implications of the covid-19 pandemic on chronic care: global perspectives from people with type 1 diabetes COVID-19 and healthcare systems: what should we do next? Public Health Endocrinology in the time of COVID-19: remodelling diabetes services and emerging innovation COVID-19, type 1 diabetes, and technology: why pediatric patients are leading the way A qualitative study of primary care physicians' experiences with telemedicine during COVID-19 A novel telemedicine protocol improved outcomes for high-risk patients with type 1 diabetes: a 3-month quality improvement project during the COVID-19 pandemic Managing new-onset type 1 diabetes during the COVID-19 pandemic: challenges and opportunities Top 10 tips for successfully implementing a diabetes telehealth program The digital/virtual diabetes clinic: the future is now-recommendations from an international panel on diabetes digital technologies introduction Pitfalls in telemedicine consultations in the era of COVID 19 and how to avoid them Telemedicine in the time of the COVID-19 pandemic: results from the first survey among Italian pediatric diabetes centers Adoption of telemedicine for type 1 diabetes care during the COVID-19 pandemic Changes to care delivery at nine international pediatric diabetes clinics in response to the COVID-19 global pandemic Use and perception of telemedicine in people with type 1 diabetes during the COVID-19 pandemic-results of a global survey Clinical effectiveness of telemedicine in diabetes mellitus: a meta-analysis of 42 randomized controlled trials A systematic review of pediatric telediabetes service models Teleconsultation in type 1 diabetes mellitus (TELEDIABE) Assessing the benefits and challenges of video consultations for the treatment of children with type 1 diabetes-a qualitative study among diabetes professionals Shaping workflows in digital and remote diabetes care during the COVID-19 pandemic via service design: prospective, longitudinal, open-label feasibility trial